Clay B Siegall is President and CEO of Immunome Inc.. Currently has a direct ownership of 519,636 shares of IMNM, which is worth approximately $5.7 Million. The most recent transaction as insider was on Nov 22, 2024, when has been sold 33,943 shares (Common Stock) at a price of $9.78 per share, resulting in proceeds of $331,962. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 520K
23.83% 3M change
62.57% 12M change
Total Value Held $5.7 Million

CLAY B SIEGALL Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 22 2024
BUY
Open market or private purchase
$331,962 $9.78 p/Share
33,943 Added 6.13%
519,636 Common Stock
Nov 21 2024
BUY
Open market or private purchase
$630,183 $9.54 p/Share
66,057 Added 11.97%
485,693 Common Stock
May 21 2024
BUY
Open market or private purchase
$281,580 $13.78 p/Share
20,434 Added 4.64%
419,636 Common Stock
May 20 2024
BUY
Open market or private purchase
$1,106,763 $13.91 p/Share
79,566 Added 16.62%
399,202 Common Stock
Oct 02 2023
BUY
Open market or private purchase
$999,995 $5.91 p/Share
169,204 Added 34.61%
319,636 Common Stock

Also insider at

SGEN
Seagen Inc. Healthcare
NRIX
Nurix Therapeutics, Inc. Healthcare
TALS
Talaris Therapeutics, Inc. Healthcare
STTK
Shattuck Labs, Inc. Healthcare
CBS

Clay B Siegall

President and CEO
Bothell, WA

Track Institutional and Insider Activities on IMNM

Follow Immunome Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IMNM shares.

Notify only if

Insider Trading

Get notified when an Immunome Inc. insider buys or sells IMNM shares.

Notify only if

News

Receive news related to Immunome Inc.

Track Activities on IMNM